A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy

Drug Safety : an International Journal of Medical Toxicology and Drug Experience
R AbrahamM D Green

Abstract

The anthracycline antibiotics comprise a group of cytotoxic compounds with wide-ranging activity against human malignancies. They are used extensively for curative, adjuvant and palliative therapy, both as single agents and in combination regimens. They produce a number of adverse effects, some of which are shared by other cytotoxic drugs. The most important adverse effect is cardiotoxicity, which is unique to this class of compounds. Strategies have been devised to circumvent these adverse effects, including the development of less toxic analogues, alterations in scheduling, the addition of cardioprotectant agents and methods of monitoring for cardiac abnormalities.

Citations

Aug 19, 2007·European Journal of Drug Metabolism and Pharmacokinetics·M PopovicB Kaurinovic
Jun 21, 2002·Clinical Pharmacokinetics·Romano DanesiMario Del Tacca
Nov 28, 2013·World Journal of Gastroenterology : WJG·Simon BinderMichael Keese
Jul 30, 2005·Expert Opinion on Investigational Drugs·Peter Borchmann, Roland Schnell
Sep 27, 2000·Neoplasia : an International Journal for Oncology Research·A W El-Kareh, T W Secomb
Apr 26, 2002·Journal of Cutaneous Pathology·Henry SkeltonKathleen Smith
May 1, 2021·Materials·Kamila ButowskaJacek Piosik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.